- Home
- INCY vs RPRX Comparison
INCY vs RPRX Comparison
Compare INCY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- RPRX
- Stock Information
- Founded
- INCY 1991
- RPRX 1996
- Country
- INCY United States
- RPRX United States
- Employees
- INCY N/A
- RPRX N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- INCY Health Care
- RPRX Health Care
- Exchange
- INCY Nasdaq
- RPRX Nasdaq
- Market Cap
- INCY 17.0B
- RPRX 16.2B
- IPO Year
- INCY 1993
- RPRX 2020
- Fundamental
- Price
- INCY $105.96
- RPRX $39.56
- Analyst Decision
- INCY Buy
- RPRX Strong Buy
- Analyst Count
- INCY 19
- RPRX 3
- Target Price
- INCY $89.19
- RPRX $46.00
- AVG Volume (30 Days)
- INCY 2.9M
- RPRX 3.6M
- Earning Date
- INCY 10-28-2025
- RPRX 11-05-2025
- Dividend Yield
- INCY N/A
- RPRX 2.22%
- EPS Growth
- INCY 3878.02
- RPRX N/A
- EPS
- INCY 5.90
- RPRX 1.75
- Revenue
- INCY $4,813,105,000.00
- RPRX $2,349,844,000.00
- Revenue This Year
- INCY $19.33
- RPRX $36.16
- Revenue Next Year
- INCY $10.47
- RPRX $2.04
- P/E Ratio
- INCY $18.34
- RPRX $22.60
- Revenue Growth
- INCY 18.09
- RPRX 3.70
- 52 Week Low
- INCY $53.56
- RPRX $24.05
- 52 Week High
- INCY $109.28
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- INCY 73.65
- RPRX 61.52
- Support Level
- INCY $91.16
- RPRX $38.39
- Resistance Level
- INCY $109.28
- RPRX $41.24
- Average True Range (ATR)
- INCY 4.54
- RPRX 1.22
- MACD
- INCY 0.92
- RPRX 0.15
- Stochastic Oscillator
- INCY 86.44
- RPRX 67.70
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.